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Simple and complex retroviral vectors derived from Moloney murine leukemia virus (MLV) and human immunodeficiency
virus type 1 (HIV-1), respectively, are useful tools for gene transfer studies. However, factors affecting the stability of these
vectors have not been carefully investigated. Here we studied the stability factors on vesicular stomatitis viral envelope
glycoprotein (VSV-G)-pseudotyped MLV- and HIV-1-derived vectors. Analysis of the ratio of defective particles versus
infectious units using electron microscopy and a functional transduction assay revealed that both vectors consisted of high
numbers of defective particles (;100–350:1), which could be reduced (;10–20:1) by centrifugation. Frequent freeze-and-
thaw rapidly decreased vector titer in the first three to five cycles and stabilized thereafter. Both viral vectors were sensitive
to temperatures above 37°C but more stable at temperatures below 37°C, exhibiting a two-phase inactivation kinetic starting
with a steep inactivation phase, followed by a more leveled phase. Interestingly, HIV-1-derived vectors were significantly
more stable than MLV-derived vectors at higher temperatures (.37°C). Both vectors were rapidly destabilized at pH either
below or above 7.0. Incubation with human or mouse serum significantly inhibited VSV-G-pseudotyped vector activities.
Preheated human serum still reduced vector half-lives to ;50% (150 min), suggesting that certain inactivation factors are not
heat-labile. Analyses of these stability factors may improve future production and applications of retroviral and lentiviral
vectors. © 2001 Academic Press
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1
t
c
e
e
t
PINTRODUCTION
Viral vectors are useful tools for gene delivery. Retro-
viral vectors require Gag-Pol and Env proteins to be
coexpressed for particle assembly. The transgene of
interest is constructed on a separate vector which, upon
infection, randomly integrates into host cell chromo-
some. These features of integration and potential long-
term transgene expression make the retroviral vector a
popular gene transfer tool for laboratory and clinical use
(Miller et al., 1993). Although integration is a necessary
step in the retroviral life cycle, for simple retroviruses
such as MLV, this process requires cell division coupled
with a breakdown of nuclear membranes, to allow nu-
clear translocation of the proviral integration complexes.
On the other hand, lentiviral vectors infect both dividing
and nondividing cells and therefore could potentially
overcome the shortcoming of the limited target range of
conventional retroviral vectors.
The stability and pharmacokinetics of both retroviral
and lentiviral vectors have not been well characterized;
such information would be valuable for both in vitro and
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124in vivo applications. Viral vector stability can be influ-
enced by various factors, including temperature, pH,
freeze-and-thaw frequency, and incubation conditions,
including growth media and serum components during
vector production and transportation.
The half-life of retroviral vectors in vivo correlates with
their in vitro resistance to serum complement (DePolo et
al., 1999) and the sensitivity of retroviral vectors to human
serum is dependent on the species of producer cells
(Cosset et al., 1995; Pensiero et al., 1996). Retroviruses
produced in murine cells have a very short half-life (,1
min) following intravenous administration in macaques
(Cornetta et al., 1990). Retroviral vectors produced from
cells expressing galactosyl (a1–3) galactosyl (aGal) are
sensitive to human serum as a result of the activities of
anti-aGal antibodies in human serum (Takeuchi et al.,
997; Welsh et al., 1998). In addition to the producer cell
ype, the type of envelope protein can also influence
omplement sensitivity of MLV (Takeuchi et al., 1994). For
xample, rapid inactivation may occur to those vectors
xpressing the xenotropic viral envelope, rather than to
hose expressing the amphotropic viral envelope (De-
olo et al., 1999). The HIV-1 and MLV vectors used in this
study were pseudotyped with the VSV-G envelope and
produced from TE671 cells, a human cell line which does
not express aGal.
We examined the physical properties and serum sen-
itivity of both lentiviral and retroviral vectors produced
w
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125STABILITY OF RETROVIRAL AND LENTIVIRAL VECTORSby two human producer cell lines (TE671 or 293). Vector
stability was monitored by an infectivity assay following
different pH, temperature, freeze-and-thaw, and mouse
or human serum treatments. We also investigated the
ratio of defective particle formation for both vector types.
The information gathered from this study will be of gen-
eral interest to preclinical and clinical researchers using
these two vector systems.
RESULTS
Ratios of defective particle versus infectious units of
retroviral and lentiviral vectors
Both retro- and lentiviruses produce defective parti-
cles during infections (Bernier and Tremblay, 1995;
Huang and Baltimore, 1970; Meyerhans et al., 1989). It is
not clear, however, what percentages of viral particles
produced by the vector-producer cells are defective fol-
lowing the DNA cotransfection protocol. In other words,
the ratios of retroviral or lentiviral particles versus their
infectious units have not been carefully examined. To
investigate this, MLV- and HIV-1-derived vectors were
prepared by DNA cotransfection in TE671 cells as pre-
viously described (Chang et al., 1999). The VSV-G-
pseudotyped viral vectors were concentrated by centrif-
ugation and the titer of each vector was determined by
b-galactosidase assay on TE671 cells. Both unconcen-
FIG. 1. Retroviral (retro) and lentiviral (lenti) vector particles mixed
with 142-nm latex beads under transmission electron microscope.
Concentrated retro- and lentiviral vector particles were prepared from
transfected TE671 cells and mixed with similar sized latex beads,
negative-stained, and examined under a transmission electron micro-
scope (Hitachi 7100). The latex beads are shown as bright white
particles. Arrowheads point to representative particles with known
retroviral morphology.trated and concentrated virus preparations were exam-
ined by mixing different dilutions of the virus samples
with a known concentration of 142-nm latex beads and
counted under EM. Representative EM pictures of retro-
viral and lentiviral vector/bead mixtures are shown in Fig.
1, and the particle versus infectious unit ratios are sum-
marized in Table 1. The ratios of particles to infectious
units for MLV- and HIV-1-derived vectors were deter-
mined to be 117:1 and 346:1, respectively, for unconcen-
trated vector particles, and 7:1 and 18:1, respectively, for
concentrated vector particles. It appears that HIV-1-de-
rived lentiviral vectors have a higher ratio of defective
particles than do MLV-derived retroviral vectors.
Biphasic freeze-and-thaw kinetics of retroviral and
lentiviral vectors
To test the effects of frequent freeze-and-thaw on vec-
tor activity, both pseudotyped retro- and lentiviral vectors
were subjected to multiple rounds of freeze-and-thaw
treatment followed by titration on TE671 cells. The viral
vectors were collected from culture supernatants and
either used for infection directly or subjected to one
round of concentration by microfuge centrifugation be-
fore infecting TE671 cells. The titers of both concentrated
and unconcentrated virus samples were determined as
described under Materials and Methods. The results are
summarized in Fig. 2. Interestingly, a biphasic infectivity
kinetic was observed for both MLV and HIV-1 vectors,
with two linear phases intercepted at the point between
the third and the fifth freeze-and-thaw cycles. This bipha-
sic kinetic is observed for both concentrated and uncon-
centrated vectors. The vector half-life was determined to
be 3.8 and 11.8 freeze-and-thaw times for the first and the
second phase, respectively, and was consistent for both
virus types and for both the high and the low concentra-
tion of samples.
The temperature effects on VSV-G-pseudotyped
retroviral and lentiviral vectors
To determine the temperature effects, retro- and
TABLE 1
Ratios of Vector Particles vs Infectious Units
Unconcentrated Concentrated
MLV HIV MLV HIV
Particles (P)/ml 2.71 3 107 9.49 3 107 6.96 3 109 1.80 3 1010
Infectious units
(IU)/ml 2.31 3 105 2.74 3 105 1 3 109 1 3 109
P/IU ratio 117 346 7 18
Note. Viral particle number (upper row) and infectious units (titer)
ere quantified under EM and by a functional transduction assay on
E671 cells, respectively.lentiviral vectors were incubated at 4, 20, 37, 45, or
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126 HIGASHIKAWA AND CHANG50°C for different periods of time and the vector titer
was then determined as described above. The vector
transduction efficiencies decreased rapidly with in-
creasing temperature for both vector types (Fig. 3A).
Based on the transduction kinetics, both HIV and MLV
are considerably unstable at room temperature with
half-lives between 1 and 2 days (Fig. 3B). The half-lives
of both vectors were markedly decreased at tempera-
tures above 4°C. At 37°C, the half-lives of HIV-1 and
MLV vectors were 10.4 6 1.2 and 4.5 6 1.0 h, respec-
tively (Fig. 3B). Interestingly, the MLV vectors were
significantly less stable than the HIV-1 vectors at
higher temperature (i.e., 37, 45, and 50°C), whereas at
low temperature (i.e., 4°C), the MLV vectors appeared
to be more stable than the HIV-1 vectors (Fig. 3B). To
simulate a chemical reaction incorporating these con-
ditions, we analyzed these data using the Arrhenius
equation; this equation expresses a logarithmic rela-
tionship between the rate constant of the vector inac-
tivation reaction and the reciprocal of the absolute
temperature. An Arrhenius plot was composed using
the b-phase rate constants of vector inactivation at 4,
0, and 37°C (Fig. 3C). The result showed that both
ectors were characterized by a break at 37°C, even
hough we chose the rate constants derived from the
b-phase obtained at 4, 20, and 37°C. A steep slope in
he Arrhenius plot means that the rate constant in-
reases dramatically as the temperature increases.
herefore, the vector inactivation kinetics consisted of
wo inactivation energy values, 61.7 kcal/mol above
7°C and 12.7 kcal/mol below 37°C for HIV-1 vectors,
nd 62.9 kcal/mol above 37°C and 9.9 kcal/mol below
FIG. 2. Freeze-and-thaw effect on retroviral and lentiviral vector titer.
nconcentrated (low concentration) and concentrated (high concentra-
ion) viral preparations were subjected to multiple freeze-and-thaw
ycles as indicated and vector titer was determined by infecting TE671
ells and performing the b-galactosidase assay as described under
aterials and Methods. The mean values of three independent exper-
ments are used for the graph.7°C for MLV vectors (Fig. 3C). whe pH effects on vector stability
We further examined vector stability under different
H conditions at no ionic strength. The pH range
ested was from 5.0 to 9.0. VSV-G-pseudotyped viral
ectors were incubated in different pH buffers pre-
ared as described under Materials and Methods. The
H was neutralized by dilution of the pH buffer, con-
aining the virus, with a high volume of culture media.
he results showed that both HIV-1 and MLV vectors
ere stable at pH 7.0, and gradually destabilized as
he pH either increased or decreased (Fig. 4). The
alf-lives of both viral vectors at pH 6.0 and pH 8.0
arkedly dropped to less than 10 min.
irus stability in human or mouse serum
To see whether vector stability could be affected by
ncubation with serum, concentrated MLV- and HIV-1-
erived vectors were mixed with either mouse or human
era (heparin-treated) at a 1:1 ratio and incubated at
7°C for different periods of time, to determine their
alf-lives. Our preliminary studies indicated that the
E671 cells used for vector titer study are extremely
ensitive to mouse serum treatment; we observed ;80%
E671 cell death after 24-h incubation with 1% of mouse
erum and ;50% cell death after 3-h incubation with 5%
f mouse serum. Likewise, we observed ;50% TE671
ell death following incubation with 10% unheated hu-
an serum. Such tissue culture serum sensitivity was
ess severe with HeLa cells. Therefore, this study was
erformed using HeLa cells as the target cells.
We compared the titers of both MLV and HIV vectors
ollowing human or mouse serum incubation at 37°C.
he results showed that unheated mouse and human
era rapidly inactivated both viral vectors, with .50%
nhibition of HIV vector activity by human serum and
90% inhibition of MLV vector activity by mouse serum,
fter a 30-min incubation (Fig. 5). The serum effect on
iral half-lives was further determined by incubation for
ifferent periods of time and the results are summarized
n Table 2. The half-lives of VSV-G-pseudotyped vectors,
oth MLV- and HIV-derived, were markedly decreased
fter incubation in unheated human or mouse sera. To
etermine whether this inhibitory effect could be elimi-
ated by heat treatment, mouse and human sera were
eated at 56°C for 30 min, which is a standard protocol
or inactivating serum complement. As illustrated in Fig.
, both MLV and HIV vectors were less affected in heated
uman sera after 30-min incubation, with HIV vectors
etaining .80% of baseline activity. To the contrary, both
LV and HIV vectors were inhibited to the same extents
n heat-treated mouse sera as compared with incubation
n unheated mouse sera for 30 min (Fig. 5). This result
uggests that the inhibitory factors present in the mouse
erum are heat-resistant. To see whether such inhibitors
ere associated with B or T immune effector cells in
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127STABILITY OF RETROVIRAL AND LENTIVIRAL VECTORSmice, we treated both HIV and MLV vectors with sera
obtained from severe combined immunodeficiency mice
(SCID) lacking both B- and T-cell functions. Compared
with human and normal mouse serum treatment, the
result showed that both HIV and MLV vectors recovered
30 and 80% activities, respectively, when treated with
SCID mouse serum (Table 2). In particular, MLV vector
function was mostly preserved under SCID serum treat-
FIG. 3. The temperature effect on VSV-G pseudotyped retroviral and
nder Materials and Methods and incubated at various temperature
emperature incubation. Values represent the means of three to five tri
he second phase (b-phase) of inactivation kinetics of (A) was used
ndicated between MLV and HIV-1 vectors, with *, P , 0.05 and ***, P
rrhenius plot. Rate constants were obtained from the b-phase inactiva
represent the means of three to five trial results.ment.DISCUSSION
In this study, we investigated retroviral and lentiviral
vector stability by measuring vector transduction effi-
ciency using TE671 or HeLa cells. Vector transduction
efficiency was determined by an enzyme assay using the
nuclear lacZ reporter gene. Through EM and titer stud-
ies, we showed that both vector systems produced high
ratios of defective particles, higher than 99%, 117:1 for the
ral vectors. Unconcentrated viral vectors were prepared as described
ifferent lengths of time. (A) Biphasic inactivation kinetics of different
Half-lives of retroviral and lentiviral vectors at different temperatures.
rmine the viral half-lives. Significant differences in viral half-lives are
5. (C) Inactivation rate constants in the range of 4 to 50°C shown as
etics of 4, 20, and 37°C incubation temperatures, respectively. Valueslentivi
s for d
als. (B)
to dete
, 0.00retroviral vectors and 346:1 for the lentiviral vectors. It
128 HIGASHIKAWA AND CHANGwas previously reported that high percentages of defec-
tive HIV particles are produced from infected tissues of
AIDS patients and by cell lines chronically infected with
HIV-1 (Bernier and Tremblay, 1995; Meyerhans et al.,
1989). Our vector production protocols employ a DNA
cotransfection method that could facilitate numerous re-
combination events. It is conceivable that the DNA co-
transfection protocol produces more defective particles
than established producer cell lines. Interestingly, such
VSV-G-pseudotyped and defective viral particles could
be markedly reduced (by 15- to 20-fold) after a simple
FIG. 4. The pH effect on vector stability. Retroviral and lentiviral
vectors were incubated under different pH conditions at 37°C for
different lengths of time (from 5 to 120 min) and subsequently used to
infect TE671 cells for titer determination. Phosphate buffer was used for
pH 5–7 and Tris–HCl buffer for pH 7–9, as described under Materials
and Methods. The titer value at pH 7 was presented as the average of
both buffer systems. The half-lives of both vectors are plotted against
different pH conditions. Mean values 6 SE of three to five trials are
presented.
FIG. 5. The serum incubation effect on VSV-G pseudotyped retroviral
and lentiviral vectors. MLV- or HIV-1-derived viral vectors were incu-
bated in human or mouse serum, heated or unheated as indicated, at
37°C for 30 min prior to titer determination. The percentages of remain-
ing vector titers relative to an unincubated control are presented.
Values represent the means 6 SE of three to five trials; The effect on
MLV vector significantly different from that of HIV-1, with *, P , 0.05 and
***, P , 0.005; the effect of heat treatment significantly different from
the corresponding unheated serum treatment is also depicted, with
††P , 0.01 and †††P , 0.005.centrifugation step. It appears that defective, low-density
viral particles are largely eliminated through centrifuga-
tion.
We further investigated factors affecting the vector
stability. The interruption of any viral replication steps
during infection, from receptor binding to proviral inte-
gration, could lead to vector inactivation. Viral proteins
such as the Gag matrix protein (MA), capsid p24 (CA),
nucleocapsid p7 (NC), reverse transcriptase (RT), inte-
grase (IN), or the pseudotyped viral envelope VSV-G
could potentially be the target of inactivation. In freeze-
and-thaw experiments, two kinetic components were ob-
served. Both HIV-1 and MLV were inactivated rapidly in
the first phase followed by a stabilized phase after five
freeze-and-thaw cycles. Because we determined vector
inactivation by functional transduction assay, the ob-
served biphasic kinetics could be explained by any of the
following two possibilities: (1) there were two popula-
tions of vector particles, one of which was more fragile
than the other, and (2) each viral particle contained two
different degradation sites or components, again, one
component of which was more fragile than the other. It
was previously reported that binding of the HIV envelope
glycoprotein (gp160) to CD4 was decreased by 50% after
two freeze-and-thaw cycles but was not further affected
by subsequent freeze-and-thaw up to 15 cycles (Papan-
dreou et al., 1996). This is consistent with our observa-
tion, although in our study the VSV-G envelope was used
as a pseudotype envelope.
The study of the temperature effects showed that MLV
vectors were less stable than HIV-1 vectors at tempera-
tures higher than 37°C, and both vectors displayed a
TABLE 2
Half-Lives of Viral Vectors in Human or Mouse Serum
Half-life (min)
HIV-1 MLV
Control
(without serum) 321.2 6 62.2 207.0 6 34.3
Human serum
(Unheated) 25.3 6 6.0* 59.2 6 8.8*,†
(Heated) 168.7 6 17.1‡‡‡ 147.6 6 27.4
Normal mouse serum
(Unheated) 34.9 6 5.0*** 2.24 6 0.47***,†††
(Heated) 33.5 6 6.1*,‡ 2.04 6 0.48***,†††
SCID mouse serum
(Unheated) 94.2 6 15.6 156.2
Note. Value represent the means 6 SE of the results from 3 to 5
trials.
* Significantly different from control without serum *P , 0.05 or
***P , 0.005.
† Significantly different from HIV-1 at †P , 0.05 or †††P , 0.005.
‡ Significantly different from each unheated serum at ‡P , 0.05 or
‡‡‡P , 0.005.biphasic inactivation kinetic. The Arrhenius plot analysis
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129STABILITY OF RETROVIRAL AND LENTIVIRAL VECTORSusing inactivation constants of the second phase (b-
phase) of the temperature incubation kinetics suggests
that there is a breaking point at or around 37°C. This type
of biphasic plot again implies that at least two compo-
nents with different inactivation kinetics are affected by
the treatment.
Compared with adenovirus and adeno-associated vi-
rus (Johnson and Bodily, 1975), both the HIV-1 and MLV
vectors are sensitive to the pH variations, in that the
inactivation rates changed dramatically under nonphysi-
ological pH conditions. Interestingly, a recent study re-
ports that a decrease in pH reduces adenovirus vector
titer during dry-ice shipment (Nyberg-Hoffman and Agui-
lar-Cordova, 1999). Thus, the storage and shipment of
HIV-1 and MLV vectors should also consider pH varia-
tions.
We also observed that both retroviral and lentiviral
vectors pseudotyped with VSV-G envelope were quite
unstable in human or mouse sera. In general, the HIV-1
vector was less stable than the MLV vector in human
serum, whereas the MLV vector was less stable than the
HIV-1 vector in mouse serum. The half-life of the VSV-G-
pseudotyped lentiviral vector was about 25 min in me-
dium containing 50% unheated human serum. Antibody
neutralization of virus particles is a common mechanism
of host defense. Thus, this serum inactivation effect
could be entirely attributed to the VSV-G-pseudotyped
envelope used in this study. VSV is a mouse pathogen
and is widespread in the western swine population, but
its association with humans is not well characterized
(Rodriguez et al., 2000). TE671-derived amphotropic mu-
rine retrovirus vectors are sensitive to inactivation by
human serum (Pensiero et al., 1996). Other studies pre-
viously demonstrated that an antibody-dependent mech-
anism may play a predominant role for vector inactivation
through aGal glycosylation epitopes in the virus particles
(Takeuchi et al., 1996). However, the VSV-G-pseudotyped
viral vectors used in this study were produced from
TE671 cells that do not express aGal. Therefore, other
inactivation mechanisms must be at play.
HIV-1 vectors were much more stable in heated hu-
man serum than in unheated serum, suggesting that
heating may have eliminated some destabilizing factors
in the human serum. However, the heated serum still
destabilized HIV-1 vectors (half-life 5 168 min) compared
to the control incubation without human serum (half-
life 5 321 min) at 37°C (Table 2). It was reported earlier
that HIV-1 RNA was slightly more unstable in heparinized
blood than in whole EDTA blood (Bruisten et al., 1997).
We compared viral vector stability in serum without hep-
arin to that with heparin for both human and mouse sera;
a slight decrease in vector half-life was observed when
heparin was used. However, the decrease was not sig-
nificant and cannot account for the inactivation activity of
the heated serum (data not shown).The half-lives of both retro- and lentiviral vectors were 1not significantly different in heated versus unheated
mouse serum. The half-life of MLV was only 2 min in the
mouse sera. The SCID mouse serum study showed that
the half-life of HIV-1 was not markedly changed (35 min
versus 94 min), whereas the stability of MLV was signif-
icantly improved (2 min versus 156 min) (Table 2). To-
gether, these data suggest that alternative factors other
than complement or functional immune cell factors are
still contributing to the serum inhibitory effects. Such
serum sensitivity can be a significant barrier to in vivo
applications of VSV-G-pseudotyped retroviral and lentivi-
ral vectors. Understanding the destabilizing mechanisms
to both retroviral and lentiviral vectors might improve
vector stability and provide useful information for future
gene therapy applications.
MATERIALS AND METHODS
Cells and culture conditions
TE671 (human rhabdomyosarcoma) and HeLa (human
cervical carcinoma) cells were obtained from ECACC
(United Kingdom) and ATCC (Rockville, MD), respectively.
Cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Mediatech, Herndon, VA) supple-
mented with 10% fetal bovine serum (FBS; Gibco BRL,
Gaithersburg, MD) and 100 units/ml of penicillin-strepto-
mycin (Gibco BRL).
Vector production and titration
A modified calcium phosphate DNA cotransfection
protocol was used for the preparation of retroviral and
lentiviral vectors in our laboratory (Chang et al., 1999).
riefly, to produce lentiviral vectors, 10 mg of
TVDEFnlacZ, 15 mg of pHPDNde/Ase, and 6 mg of
HEF-VSVG were cotransfected with 0.5 mg of a tat-
encoding plasmid pCEP4tat into TE671 cells (8 3 105) in
a six-well tissue-culture plate. To produce retroviral vec-
tors, 10 mg of pLFGEFnlacZ, 20 mg of pcDNAEFgagpol,
nd 6 mg of pHEF-VSVG were cotransfected into TE671
cells. Culture media were changed 18–24 h after DNA
was added, and the virus was harvested three to four
times at 12-h intervals. Virus supernatant was filtered
through a 0.45-mm low-protein binding filter (Millex-HV;
illipore, Bedford, MA) to remove cell debris. For pH,
reeze-and-thaw, or human and mouse serum experi-
ents, both HIV-1 and MLV were concentrated by cen-
rifugation in a microcentrifuge at full speed (14,000 rpm)
sing the F45-30-11 rotor (Eppendorf, Hamburg, Ger-
any) at 4°C for 2–3 h. The microcentrifuge protocol
outinely recovers .95% of the infectious units and
reeze-and-thaw does not appear to have any impact on
his concentration protocol. The supernatants were
tored at 280°C in aliquots until use. To determine the
ector titer, two different dilutions were used to infect 6 3
04 TE671 cells, which were plated into a 24-well plate, in
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130 HIGASHIKAWA AND CHANGa final volume of 0.2 ml containing 8 mg/ml of Polybrene
(Sigma, St. Louis, MO). After 3–4 h of infection, 0.5 ml of
fresh media was added and, 48 h after infection, cells
were fixed and stained with X-gal substrate as previously
described (Chang et al., 1999). Virus titer was determined
by counting the blue nucleated cells under an inverted
microscope.
Virus particle quantification under electron
microscopy
MLV- and HIV-1-derived vectors were prepared by
DNA cotransfection into TE671 cells as described above.
The VSV-G-pseudotyped vectors were concentrated by
microfuge centrifugation and the titer of each vector was
determined by the b-galactosidase assay on TE671 cells.
hese virus specimens were fixed with a 2% buffered-
lutaraldehyde solution, diluted if needed, and mixed at
1:1 (v/v) ratio with a known concentration of 142-nm
atex beads. The mixtures were centrifuged directly onto
copper mesh grid in a Beckman Airfuge ultracentrifuge
icrotube (Beckman Instruments, Fullerton, CA), nega-
ive-stained with phosphotungstic acid, and examined
nder a transmission electron microscope (Hitachi 7100)
s previously described (Alain et al., 1987). Particles,
efective or not, with preserved retroviral morphology
ere counted and the results were consistent with two to
hree different preparations. The concentration of virus in
he suspension was determined from the ratio of viral
nd latex particles, the ratio of viral suspension to bead
uspension, and the known bead concentration.
IV p24 ELISA
The concentration of HIV Gag p24 was determined
sing a commercial HIV-1 p24 Antigen Capture Assay Kit
Biological Products Laboratory, Frederick Cancer Re-
earch and Development Center, Frederick, MD).
reeze-and-thaw preparation of viral vectors
The virus was frozen rapidly either on dry ice or in
iquid nitrogen and stored at 280°C before being thawed
ompletely at 37°C for 5 min and used to infect TE671
ells. This procedure was repeated for multiple freeze-
nd-thaw cycles.
emperature and pH adjustment
Viral vectors were incubated at various temperatures
n a water bath: 4, 20, 37, 45, and 50°C for different
engths of time and used to infect TE671 cells. Different
H solutions were prepared as follows: 0.1 M phosphate
uffer was used for the preparation of pH 5.0, 6.0, 7.0,
nd 0.1 M Tris–HCl buffer was used for the preparation of
H 7.0, 8.0, and 9.0. The mixture of 95 ml of buffer solution
with 5 ml of concentrated virus was incubated at 37°C for
different periods of time and used to infect TE671 cells.Two different volumes of virus were used, 10 and 20 ml,
each of which was adjusted to a total 200 ml of media
including Polybrene.
Incubation of viral vectors in human and mouse sera
Heat treatment of serum was performed by incubating
the serum at 56°C for 30 min. Virus and serum were then
mixed at a 1:1 ratio and incubated at 37°C for different
lengths of time. The incubation was stopped on ice and
the virus/serum mixture was used to infect HeLa cells
immediately using two different volumes, 5 and 8 ml. At
the same time, a control untreated virus sample was also
used to infect HeLa cells.
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